Back to top

Image: Bigstock

Fate Therapeutics (FATE) Jumps: Stock Rises 5.7%

Read MoreHide Full Article

Fate Therapeutics, Inc.  (FATE - Free Report)  was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $3.94–$4.65 in the past one-month time frame, witnessed a sharp increase yesterday.

Fate Therapeutics has seen three negative estimate revisions over the past two months. The Zacks Consensus Estimate for the current quarter has also revised downward over the same time frame, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.  

Fate Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.

Fate Therapeutics, Inc. Price and Consensus

Another stock in the Biomedical and Genetics industry is Protagonist Therapeutics, Inc. (PTGX) which carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is FATE going up? Or down? Predict to see what others think: Up or Down

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.

See Them Free>>


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Fate Therapeutics, Inc. (FATE) - free report >>

Published in